Mesoblast has successfully met the pre-specified primary endpoint, prospectively agreed with FDA, of a single-arm Phase 3 trial in 54 children with SR-aGvHD. While the Oncologic Drugs Advisory Committee of FDA in August 2020 voted 9:1 in favor of remestemcel-L’s efficacy in a pediatric patient population, in September 2020 FDA recommended further steps be undertaken to obtain approval. The BLA resubmission of January 2023 included long-term follow-up data from the Phase 3 trial by the Center for International Blood and Marrow Transplant Research (CIBMTR) showing 50% survival through more than 4 years of follow-up for remestemcel-L treated patients in the Phase 3 trial for whom less than 20% survival at two years was expected based on disease severity. The resubmission also included a post-hoc propensity matched study showing 6 month survival was 67% with remestemcel-L vs 10% with other unapproved therapies in highest-risk patients as identified using the Mount Sinai Acute GVHD International Consortium (MAGIC). These pediatric data provide further support for use of remestemcel- L in the proposed study in high-risk adults with SR-aGVHD.
Fxxx the Corrupt FDA, I am finished
Last post for me, bye all
Howie
- Forums
- ASX - By Stock
- Ann: Update on BLA for Graft Versus Host Disease
Mesoblast has successfully met the pre-specified primary...
- There are more pages in this discussion • 889 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
-0.045(3.83%) |
Mkt cap ! $1.290B |
Open | High | Low | Value | Volume |
$1.18 | $1.19 | $1.12 | $12.16M | 10.69M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 50650 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.14 | 124897 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 40650 | 1.130 |
10 | 268778 | 1.125 |
18 | 237000 | 1.120 |
9 | 74675 | 1.115 |
10 | 95658 | 1.110 |
Price($) | Vol. | No. |
---|---|---|
1.140 | 124897 | 8 |
1.145 | 103108 | 3 |
1.150 | 50200 | 5 |
1.155 | 110794 | 4 |
1.160 | 17326 | 3 |
Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.13 |
  |
Change
-0.045 ( 4.33 %) |
|||
Open | High | Low | Volume | ||
$1.17 | $1.17 | $1.12 | 1447014 | ||
Last updated 15.59pm 08/05/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online